Intracellular amyloid-beta binding (ERAB) polypeptide-related assays
AssigneeThe Trustees of Columbia University in the City of New York
InventorsDavid M. Stern, Shi Du Yan
Life of this patent
Estimating the term…
Abstract
The present invention provides an isolated nucleic acid encoding an endoplasmic reticulum associated amyloid-beta peptide binding (ERAB) polypeptide. The ERAB polypeptide may comprise human ERAB polypeptide. The present invention provides a purified ERAB polypeptide, as well as a method for treating a neurodegenerative condition in a subject which comprises administering to the subject an agent in amount effective to inhibit ERAB polypeptide binding to amyloid-beta peptide so as to thereby treat the neurodegenerative condition.
Claims5
A method for determining whether an agent inhibits binding of human ERAB polypeptide (SEQ. ID. NO:
- 2), or a fragment thereof, to amyloid-beta peptide which comprises:
- (a) incubating human ERAB polypeptide (SEQ. ID. NO:
- 2), or a fragment thereof, the agent and amyloid-beta peptide under suitable binding conditions;
- (b) determining the amount of amyloid-beta peptide bound to the polypeptide or fragment from the incubate of (a);
- and
- (c) comparing the amount of bound amyloid-beta peptide determined in step (b) to an amount of amyloid-beta peptide bound to the polypeptide or fragment determined in the absence of the agent, wherein when the amount of amyloid-beta polypeptide bound to the polypeptide or fragment thereof is decreased in the presence of said agent, the agent inhibits binding of human ERAB polypeptide (SEQ. ID. NO:
- 2), or the fragment thereof.
Dependencies are inferred from the claim text.